ev3 Expanding Vascular Presence Via $95 Mil. IntraTherapeutics Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Private equity investor Warburg Pincus' ev3, Inc. unit is looking to build its peripheral vascular disease business through the purchase of Centerpulse subsidiary IntraTherapeutics for $95 mil. cash
You may also be interested in...
Terumo’s $170 Mil. Vascutek Purchase Builds Cardiovascular Offerings
Terumo Medical's annual sales will approach $230 mil. through the purchase of Centerpulse's Vascutek vascular graft division. A definitive purchase agreement was announced Oct. 4
Terumo’s $170 Mil. Vascutek Purchase Builds Cardiovascular Offerings
Terumo Medical's annual sales will approach $230 mil. through the purchase of Centerpulse's Vascutek vascular graft division. A definitive purchase agreement was announced Oct. 4
Centerpulse Divestitures Could Make Remaining Firm Attractive To Acquirers
Centerpulse's plan to divest its cardiac and vascular divisions to focus on its core orthopedics business suggests that the Swiss firm may be positioning itself for an eventual sale to a larger player in that arena